Document is current
Any future updates will be listed below
-
Authors
Czyzyk, Daniel https://orcid.org/0000-0002-2398-5784
Yan, Wupeng
Messing, Simon https://orcid.org/0000-0001-8991-2097
Gillette, William
Tsuji, Takashi
Yamaguchi, Mitsuhiro
Furuzono, Shinji
Turner, David M.
Esposito, Dominic https://orcid.org/0000-0002-9987-1687
Nissley, Dwight V. https://orcid.org/0000-0001-7523-116X
McCormick, Frank https://orcid.org/0000-0002-6619-7120
Simanshu, Dhirendra K. https://orcid.org/0000-0002-9717-4618
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (75N91019D00024)
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 19 December 2024
First Online: 9 January 2025
Competing interests
: All authors, except F.M., have no competing interests. F.M. is a consultant for Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, Pfizer, Daiichi Sankyo, Amgen, PMV Pharma, OPNA-IO, and Quanta Therapeutics, has received research grants from Boehringer-Ingelheim, and is a consultant for and cofounder of BridgeBio Pharma.
